EW vs. STE, ISRG, ZBH, ALGN, DXCM, MRNA, COR, ALC, IDXX, and TAK
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include STERIS (STE), Intuitive Surgical (ISRG), Zimmer Biomet (ZBH), Align Technology (ALGN), DexCom (DXCM), Moderna (MRNA), Cencora (COR), Alcon (ALC), IDEXX Laboratories (IDXX), and Takeda Pharmaceutical (TAK). These companies are all part of the "medical" sector.
STERIS (NYSE:STE) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment.
Edwards Lifesciences has a net margin of 23.01% compared to Edwards Lifesciences' net margin of 6.95%. STERIS's return on equity of 22.86% beat Edwards Lifesciences' return on equity.
In the previous week, Edwards Lifesciences had 5 more articles in the media than STERIS. MarketBeat recorded 20 mentions for Edwards Lifesciences and 15 mentions for STERIS. Edwards Lifesciences' average media sentiment score of 0.77 beat STERIS's score of 0.72 indicating that STERIS is being referred to more favorably in the media.
STERIS presently has a consensus target price of $241.60, suggesting a potential upside of 3.83%. Edwards Lifesciences has a consensus target price of $93.88, suggesting a potential upside of 5.31%. Given STERIS's stronger consensus rating and higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than STERIS.
STERIS has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Edwards Lifesciences received 987 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 71.82% of users gave Edwards Lifesciences an outperform vote while only 58.51% of users gave STERIS an outperform vote.
Edwards Lifesciences has higher revenue and earnings than STERIS. Edwards Lifesciences is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.
94.7% of STERIS shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 1.0% of STERIS shares are held by company insiders. Comparatively, 1.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Edwards Lifesciences beats STERIS on 14 of the 18 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edwards Lifesciences Competitors List
Related Companies and Tools
